BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
20 juil. 2015 08h30 HE
|
BioMarin Pharmaceutical Inc.
ABRAZO Phase 2 Study Meets Protocol-Specified Criteria to Expand Enrollment
EMBRACA Phase 3 Study Enrollment Completion Targeted 1H 2016
SAN RAFAEL, Calif., July 20, 2015 (GLOBE NEWSWIRE) --...
BioMarin to Host Second Quarter 2015 Financial Results Conference Call and Webcast on Monday, August 3 at 4:30pm ET
15 juil. 2015 08h30 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
29 juin 2015 08h30 HE
|
BioMarin Pharmaceutical Inc.
FDA Grants Priority Review Status
FDA PDUFA Date is December 27, 2015
SAN RAFAEL, Calif., June 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the U.S....
BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
25 juin 2015 16h01 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Medicines Agency (EMA) has validated the Marketing Authorization...
BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study
17 juin 2015 16h01 HE
|
BioMarin Pharmaceutical Inc.
- 50% Increase in mean annualized growth velocity in 15 µg/kg/daily dose group
- BMN 111 was well tolerated across all three dose cohorts
- Phase 2 findings support program advancement of...
BioMarin CEO Jean-Jacques Bienaime Awarded EY Entrepreneur Of The Year(R) 2015 Award in Northern California in Health and Life Sciences
15 juin 2015 08h30 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that EY awarded BioMarin CEO Jean-Jacques Bienaimé the EY Entrepreneur Of The...
BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
08 juin 2015 08h30 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European Medicines...
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
04 juin 2015 16h05 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...
BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th; Bank of America Merrill Lynch 2015 Health Care Conference on May 13th; and, the UBS Global Healthcare Conference on May 19th
01 mai 2015 08h00 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., May 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer at BioMarin,...
BioMarin Announces First Quarter 2015 Financial Results and Company Update
30 avr. 2015 16h01 HE
|
BioMarin Pharmaceutical Inc.
- Vimizim Sales Top $50 million in First Quarter of 2015 and $127 million in First Four Quarters Since Launch
- Full-year Vimizim Guidance Increased to $200 million to $220 million; Full-year...